Opportunity Information: Apply for RFA FD 15 029
Apply for RFA FD 15 029
- The Food Drug Administration in the health information and statistics sector is offering a public funding opportunity titled "Molecular Characterization of Multiple Myeloma Ethnic Disparity" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.103 Food and Drug AdministrationResearch.
- This funding opportunity was created on May 22, 2015 and posted on May 22, 2015.
- Applicants must submit their applications by Jul 21, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $278,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $172,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligibility is limited to the Multiple Myeloma (MM) service of Memorial Sloan Kettering Cancer Institute.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity titled "Molecular Characterization of Multiple Myeloma Ethnic Disparity" (Funding Opportunity Number RFA-FD-15-029) is a Food and Drug Administration (FDA) discretionary grant designed to support a focused research project examining why Multiple Myeloma (MM) appears to differ between patients of Black ethnicity and those of White ethnicity. The central aim is to identify and compare the molecular characteristics of MM across these groups, with the broader public health intent of clarifying the biological basis of observed disparities. By generating stronger scientific evidence about potential molecular differences, the project is meant to inform how therapies are evaluated, how future clinical trials are designed, and how drug approval decisions can account for variation that may be tied to ethnicity-linked patterns in disease biology.
This opportunity uses a cooperative agreement funding mechanism, meaning the FDA expects to have substantial involvement in the project beyond simply providing funds, typically through scientific collaboration, coordination, and oversight consistent with the agency's mission. The activity category is listed under Health Information and Statistics, reflecting an emphasis on generating actionable biomedical and translational evidence that can shape regulatory science and the evidentiary standards used in drug development. The award structure indicates that one award was expected, with an estimated total funding amount of $278,000. The award ceiling and floor were both set at $172,000, indicating a fixed single-year award amount for that component, while the larger total figure suggests additional planned or associated support across the project period as described in the full announcement.
Eligibility for this grant was restricted: applications were limited to the Multiple Myeloma service of Memorial Sloan Kettering Cancer Institute. This type of limitation is sometimes used when an agency intends to support a highly specific collaboration, leverage an established patient cohort and specialized infrastructure, or quickly address a narrow scientific question where a particular institution is uniquely positioned to execute the work. There was no cost-sharing or matching requirement, so the recipient was not required to contribute additional non-federal funds to receive the award.
Key administrative details include the posting and creation date of May 22, 2015, with an original and current closing date of July 21, 2015, and an archive date of August 20, 2015, indicating the opportunity is no longer open. The CFDA number associated with the award is 93.103, aligning it with FDA research-related assistance programs. For operational questions, the point of contact listed was Vieda Hubbard, Grants Management Specialist at the FDA, with phone number (240) 402-7588 and email vieda.hubbard@fda.hhs.gov, specifically for assistance accessing the full announcement or related application materials.
In practical terms, the research supported by this opportunity is positioned as regulatory-relevant science: it is not just aimed at describing differences in MM, but at determining whether any molecular distinctions have implications for treatment response, evaluation of benefit-risk, and the representativeness of clinical trial populations. The intended outcome is evidence that can help the FDA and the broader research community interpret disparities more accurately and design future studies in ways that improve relevance and fairness in drug development and clinical research for MM.
Frequently Asked Questions (FAQs)
What is the title and funding opportunity number for this grant?
The opportunity is titled "Molecular Characterization of Multiple Myeloma Ethnic Disparity" and the Funding Opportunity Number is RFA-FD-15-029.
Which federal agency is offering this funding opportunity?
This is a Food and Drug Administration (FDA) discretionary grant.
What health condition is the research focused on?
The funded research is focused on Multiple Myeloma (MM).
What is the main purpose of the project described in the opportunity?
The central aim is to identify and compare the molecular characteristics of Multiple Myeloma in patients of Black ethnicity and patients of White ethnicity, to help clarify the biological basis of observed disparities.
Why does the opportunity emphasize ethnic disparity in Multiple Myeloma?
The opportunity is designed to examine why Multiple Myeloma appears to differ between patients of Black ethnicity and those of White ethnicity, with the intent of generating stronger scientific evidence about potential molecular differences that may relate to observed disparities.
How is this research intended to be used from a public health and regulatory perspective?
The project is positioned as regulatory-relevant science. The intended use of the evidence includes informing how therapies are evaluated, how future clinical trials are designed, and how FDA drug approval decisions can account for variation that may be tied to ethnicity-linked patterns in disease biology.
Does the opportunity focus only on describing differences, or also on implications for treatment and trials?
It is not limited to describing differences. The opportunity specifically frames the work as determining whether molecular distinctions have implications for treatment response, evaluation of benefit-risk, and the representativeness of clinical trial populations.
What funding mechanism is used for this opportunity?
The opportunity uses a cooperative agreement mechanism.
What does a cooperative agreement imply about FDA involvement?
A cooperative agreement means the FDA expects substantial involvement in the project beyond providing funds, typically through scientific collaboration, coordination, and oversight consistent with the agency's mission.
What is the activity category for this award?
The activity category is listed as Health Information and Statistics.
How many awards were expected to be made?
One award was expected.
What is the estimated total funding amount mentioned in the opportunity?
The estimated total funding amount is $278,000.
What are the award ceiling and floor amounts?
The award ceiling and the award floor were both listed as $172,000, indicating a fixed single-year award amount for that component.
Why do the total funding amount and the ceiling/floor amounts look different?
Based on the provided description, the $172,000 ceiling/floor suggests a fixed single-year component, while the larger $278,000 figure suggests additional planned or associated support across the project period as described in the full announcement.
Was cost sharing or matching required?
No. There was no cost-sharing or matching requirement, so the recipient was not required to contribute additional non-federal funds to receive the award.
Who was eligible to apply for this opportunity?
Eligibility was restricted to the Multiple Myeloma service of Memorial Sloan Kettering Cancer Institute.
Can other institutions or organizations apply?
No. The opportunity limited applications to the Multiple Myeloma service of Memorial Sloan Kettering Cancer Institute.
Why was eligibility restricted to a specific institution/service?
The provided information notes that such a limitation can be used when an agency intends to support a highly specific collaboration, leverage an established patient cohort and specialized infrastructure, or quickly address a narrow scientific question where a particular institution is uniquely positioned to execute the work.
What are the key dates for this funding opportunity?
The posting and creation date was May 22, 2015. The original and current closing date was July 21, 2015. The archive date was August 20, 2015.
Is this funding opportunity still open?
No. The archive date (August 20, 2015) and the closing date (July 21, 2015) indicate the opportunity is no longer open.
What CFDA number is associated with this opportunity?
The CFDA number associated with the award is 93.103.
Who is the point of contact for questions about the announcement or materials?
The point of contact listed is Vieda Hubbard, Grants Management Specialist at the FDA.
What contact information is provided for the grants management point of contact?
Phone: (240) 402-7588. Email: vieda.hubbard@fda.hhs.gov. The contact was specifically provided for assistance accessing the full announcement or related application materials.
What is the broader intended outcome of the funded research?
The intended outcome is evidence that can help the FDA and the broader research community interpret disparities more accurately and design future studies in ways that improve relevance and fairness in drug development and clinical research for Multiple Myeloma.
Browse more opportunities from the same category: Health Information and Statistics
Next opportunity: SOLAR BANKABILITY DATA TO ADVANCE TRANSACTIONS AND ACCESS (SB DATA)
Previous opportunity: Pakistan FELTP Human/Animal Disease Investigation and Technical Assistance to the Pakistan Ministry of Health and Ministry of Agriculture
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA FD 15 029
[Watch] how do funding administrators access proposals?
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA FD 15 029", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.